CNIPA.AI

Company patentsOncology medicines and biopharmaceuticals

COMPANY PATENT INTELLIGENCE

BeOne Medicines Patent Portfolio Analysis

Explore antibody and formulation technologies through reviewed current and historical names of BeOne Medicines and its Swiss subsidiary.

Partial name or date coverage · counts are lower boundsData as of 2026-11-17Data scope
Search jurisdictions
Worldwide
Applicant-name basis
Dataset-harmonized assignees (not verified current owners)
Source search matches
385
Published 2025-01-01 — 2025-12-31 · Source Google Patents
Applicant names included in these statistics
BEIGENE LTD · BEIGENE SWITZERLAND GMBH · BEONE MEDICINES I GMBH
Publication dates collected
Not recorded in this snapshot
Reviewed names not covered
BEIGENE, LTD. · BEONE MEDICINES LTD. · 百济神州有限公司
Compare with other companies
Collected patent publications

≥385docs

32 per month · peak 2025-03 (43)

Empty dashed outlines are uncollected periods, not zero. Dashed bars have partial name or date coverage.

01Key figures

Applications
376
By application number; publication and grant count once
Invention
205
55% of applications
Utility model
0
0% of applications
Patent families
134
By the source family ID
Green technology
—
The source has no CPC codes
Concentration
1.24HHI
Sum of squared field shares; higher is more concentrated

INSIGHT 01Fact

91%

91% of applications are in Pharmaceuticals

337 applications in this field, 322 of them in IPC A61K — the main axis of the portfolio.

Method: Field applications ÷ applications with IPC

02Technology landscape

372 applications with IPC codes are mapped to 35 fields using the WIPO IPC–Technology Concordance; area is the number of applications. Select a tile to see its IPC subclasses. An application can belong to several fields.

  • Electrical engineering
  • Instruments
  • Chemistry
Explore reviewed themes, sample patents and evidence

03Rhythm

Publications per month in each field; brighter cells mean more. It shows which directions surge in particular months.

This chart covers collected documents published from 2025-01-01 to 2025-12-31. Examination and publication processes affect this timing; it does not directly measure R&D investment in the same period.

Cells count publications only within the collected names and dates. Missing periods are not shown; the company portfolio is incomplete.
Technology field25-0125-0225-0325-0425-0525-0625-0725-0825-0925-1025-1125-12
Pharmaceuticals253538283429193221253920
Organic fine chemistry141917192115101912172716
Biotechnology7122071891181117142
Analysis of biological materials101000000000
Medical technology000000001000
Chemical engineering000001000000
Computer technology100000000000

Filing years of the collected applications

Documents in the current publication window are deduplicated by application number and grouped by filing year. These are not the company's complete annual filings; older applications may only be published or granted within this window.

  • 20131
  • 20164
  • 20177
  • 20183
  • 201914
  • 20208
  • 20219
  • 202216
  • 2023100
  • 2024113
  • 2025101Publication lag may still apply

Invention applications are generally published about 18 months after filing, or priority where claimed, and may be published earlier. Flags are estimated as of 2026-11-17. An unflagged year is still not necessarily complete; these counts cannot establish growth or contraction in R&D.

Multi-year evolution · With a longer collection window, this becomes a yearly view that marks the fastest-growing and shrinking fields.

04Strategy profile

Four reproducible structural ratios, with the other published companies on the same scale. Entity scopes and windows can differ, so read relative positions only — this is not a ranking.

Concentration

1.24
0.001.43

Position 1 of 26 published companies.

Method: Sum of squared field shares

Utility model share

0%
0%33%

Position 9 of 26 published companies.

Method: Utility model documents ÷ all documents

Green technology share

—

The source has no CPC codes, so this cannot be computed.

Method: Documents with CPC Y02 ÷ documents with CPC

Manufacturing and inspection share

0.3%
0%50%

Position 24 of 26 published companies.

Method: Applications in measurement, chemical engineering, handling and machine tools ÷ all applications

05Collaboration

Organisations that filed jointly with the collected entities; line weight represents joint applications. Name-based candidates and reviewed relationships are labeled separately. Co-applications alone do not prove ownership.

BEIGENE SUZHOU CO LTD6Other co-applicant · relationship unverified
ONYX PHARMA INC6Other co-applicant · relationship unverified
TSAI CHARNG SHENG5Other co-applicant · relationship unverified
XUE LIU5Other co-applicant · relationship unverified
CHEN YUN3Other co-applicant · relationship unverified
DING YAO3Other co-applicant · relationship unverified
JI RUYUE3Other co-applicant · relationship unverified
SPRINGWORKS THERAPEUTICS INC3Other co-applicant · relationship unverified
BEIGENE GUANGZHOU BIOLOGICS MFG CO LTD2Other co-applicant · relationship unverified
LEI MING2Other co-applicant · relationship unverified

Possible affiliation is a review lead only. Co-applicants without a review record are not automatically group members or external partners, and their independent filings are not added to these statistics.

Review the entity list

06Entities and scope

Entity review and data coverage are separate facts. This list shows the current entity configuration, evidence and relationship dates, matched name by name against this snapshot.

Filters change only the entity list below, not the statistics. A complete group snapshot is not available to switch to on this page.

Showing 2 of 2 entities

BeOne Medicines I GmbH

SubsidiaryVerifiedAll configured names covered
Names collected in this snapshot
BeOne Medicines I GmbH · BeiGene Switzerland GmbH
Recorded relationship dates
Not recorded — Not recorded

2025-05-27 母公司英文名称改为 BeOne Medicines Ltd.;合同明确 BeOne Medicines I GmbH 原名 BeiGene Switzerland GmbH。历史标准名按法人证据归并,不将全部 BeiGene/BeOne 前缀自动纳入。

Review evidence

BeOne Medicines Ltd.

Primary entityVerifiedSome names covered
Names collected in this snapshot
BEIGENE LTD
Names outside this snapshot
BeOne Medicines Ltd. · BeiGene, Ltd. · 百济神州有限公司
Recorded relationship dates
Not recorded — Not recorded

2025-05-27 母公司英文名称改为 BeOne Medicines Ltd.;合同明确 BeOne Medicines I GmbH 原名 BeiGene Switzerland GmbH。历史标准名按法人证据归并,不将全部 BeiGene/BeOne 前缀自动纳入。

Review evidence

Relationship dates help interpret renaming, acquisitions and joint ventures. Missing dates do not establish an indefinite relationship or verify the current patent owner.

07Observations

Written by editors after reading the patent texts and company materials. Verified facts and inferences are labeled, each with evidence and limits.

Technology themes and evidence

Select a theme to filter reviewed patents and observations that cite them. Counts are editorial samples only; one patent may belong to several themes. They do not describe the full portfolio distribution.

Themes describe the technical directions in these samples. Links to adoption in specific products, commercialization or commercial value have not been established.

Showing 2 sample patents · 0 linked observations

Reading samples

Hand-picked documents that illustrate technology themes — not a ranking of core patents and not representative of the whole.

US20250034257A1

Stable high concentration arginine formulations containing pd-1 antibody and methods of use thereof

The abstract concerns viscosity and stability of anti-PD-1 formulations. Claim 1 combines approximately 10–200 mg/mL antibody, a buffer at about pH 5.0–7.0, a viscosity reducer and a non-ionic surfactant, with viscosity no greater than 35 cP and a specified osmolarity range. Although the title mentions arginine, this claim uses the broader term viscosity reducer.

Bibliography and claim evidence
Applicants
Beigene Switzerland Gmbh
Application date
2024-10-11
Publication date
2025-01-30
English summary of cited claim evidence
US20250034257A1, claim 1 (reading note, not a verbatim quotation)The abstract concerns viscosity and stability of anti-PD-1 formulations. Claim 1 combines approximately 10–200 mg/mL antibody, a buffer at about pH 5.0–7.0, a viscosity reducer and a non-ionic surfactant, with viscosity no greater than 35 cP and a specified osmolarity range. Although the title mentions arginine, this claim uses the broader term viscosity reducer.
Legal status
Legal status and current ownership are unverified; applicant names retain the original source attribution.

US20250115671A1

Anti-ccr8 antibodies and methods of use

The abstract presents antibodies and antigen-binding fragments that bind human CCR8. Claim 1 specifies three heavy-chain CDR alternatives paired with defined light-chain CDR sequences, differing in selected heavy-chain regions. It supports a reading of particular antibody structures, not a conclusion that a corresponding therapy is approved.

Bibliography and claim evidence
Applicants
Beigene, Ltd.
Application date
2024-10-29
Publication date
2025-04-10
English summary of cited claim evidence
US20250115671A1, claim 1 (reading note, not a verbatim quotation)The abstract presents antibodies and antigen-binding fragments that bind human CCR8. Claim 1 specifies three heavy-chain CDR alternatives paired with defined light-chain CDR sequences, differing in selected heavy-chain regions. It supports a reading of particular antibody structures, not a conclusion that a corresponding therapy is approved.
Legal status
Legal status and current ownership are unverified; applicant names retain the original source attribution.

08Publication jurisdictions

25 publication offices · 385 documents

Counts use the publication office of each collected document, retaining publications from the same family in different jurisdictions. This is not a map of complete families, granted or active rights; WO and EP denote international and European publication routes.

  1. EPEuropean Patent Office publication66
  2. USUnited States65
  3. WOPCT international publication33
  4. ILIsrael30
  5. MXMexico30
  6. KRSouth Korea29
  7. AUAustralia27
  8. TWTaiwan25
Show 17 more jurisdictions
  1. ARArgentina22
  2. COColombia16
  3. CLChile13
  4. CNChina8
  5. JPJapan8
  6. LTLithuania2
  7. DKDenmark1
  8. ESSpain1
  9. FIFinland1
  10. HRCroatia1
  11. HUHungary1
  12. LULuxembourg1
  13. NZNew Zealand1
  14. PLPoland1
  15. PTPortugal1
  16. SISlovenia1
  17. ZASouth Africa1

09Documents

385 published documentsNewest first
  1. EP4222150B1

    Invention grant

    3-[(1h-pyrazol-4-yl)oxy]pyrazin-2-amine compounds as hpk1 inhibitor and use thereof

    BEONE MEDICINES I GMBH

    Organic fine chemistryPharmaceuticals

    2025-12-31
  2. Derivados de 5-amino-6,8-dihidro-1h-furo[3,4-d]pirrolo[3,2-b]piridin-2-carboxamida como inhibidores cooperativos con mta de prmt5

    BEONE MEDICINES I GMBH

    Organic fine chemistryPharmaceuticals

    2025-12-26
  3. EP4457224A4

    Invention publication

    Heterocyclic compounds

    BEONE MEDICINES I GMBH

    Organic fine chemistryPharmaceuticals

    2025-12-24
  4. EP4476219A4

    Invention publication

    Heterocyclic compounds, compositions thereof, and methods of treatment therewith

    BEIGENE LTD

    Organic fine chemistryPharmaceuticals

    2025-12-24
  5. EP4499630A4

    Invention publication

    Bcl-xl inhibitors

    BEIGENE LTD

    Organic fine chemistryPharmaceuticals

    2025-12-24
  6. Compound as b-raf kinase dimer inhibitor and preparation method thereof

    BEIGENE LTD

    Organic fine chemistryPharmaceuticals

    2025-12-21
  7. US2025382384A1

    Invention publication

    MUC1 Antibodies and Methods of Use

    BEONE MEDICINES I GMBH

    Biotechnology

    2025-12-18
  8. EP4661913A1

    Invention publication

    Self-stabilizing linker conjugates

    BEONE MEDICINES I GMBH

    Organic fine chemistryPharmaceuticals

    2025-12-17
  9. Co-administration of mirdametinib and lifirafenib for use in treating cancers

    BEIGENE LTD / SPRINGWORKS THERAPEUTICS INC

    Pharmaceuticals

    2025-12-15
  10. A Medicament and Method of Treatment of Central Nervous System and/or Neuropsychiatric Disorders

    BEIGENE SWITZERLAND GMBH / MASSEY VENTURES LTD

    Pharmaceuticals

    2025-12-11
  11. EP4658650A1

    Invention publication

    Heterocyclic compounds

    BEONE MEDICINES I GMBH

    Organic fine chemistryPharmaceuticals

    2025-12-10
  12. EP4658655A1

    Invention publication

    Condensed heterocyclic compounds as inhibitor of diacylglycerol kinases

    BEONE MEDICINES I GMBH

    Organic fine chemistryPharmaceuticals

    2025-12-10
  13. EP4658656A1

    Invention publication

    Condensed heterocyclic compounds as inhibitor of diacylglycerol kinases

    BEONE MEDICINES I GMBH

    Organic fine chemistryPharmaceuticals

    2025-12-10
  14. Conjugados de enlace autoestabilizantes

    BEONE MEDICINES I GMBH

    Organic fine chemistryPharmaceuticals

    2025-12-09
  15. Anticuerpos multiespecíficos anti–cd3 y métodos de uso

    BEONE MEDICINES I GMBH

    BiotechnologyPharmaceuticals

    2025-12-09
  16. Conjugados de enlace autoestabilizantes

    BEONE MEDICINES I GMBH

    Organic fine chemistryPharmaceuticals

    2025-12-05
  17. Targeted pyrrolobenzodiazapine conjugates

    BEONE MEDICINES I GMBH

    Organic fine chemistryPharmaceuticals

    2025-12-04
  18. Compounds for the degradation of egfr kinase

    BEONE MEDICINES I GMBH

    Organic fine chemistryPharmaceuticals

    2025-12-04
  19. US2025368653A1

    Invention publication

    Solid forms comprising (s)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidine-3-carboxamide, and oxalic acid, compositions and methods of use thereof

    BEIGENE SWITZERLAND GMBH

    Organic fine chemistry

    2025-12-04
  20. KR20250169624A

    Invention publication

    표적화된 피롤로벤조디아자핀 접합체

    BEONE MEDICINES I GMBH

    Organic fine chemistryPharmaceuticals

    2025-12-03

Titles come from the source bibliography. Select a number to read the full document on this site.

Drafting a patent in this field?

Upload your invention disclosure and get an editable draft that follows CNIPA practice.

Start drafting

10Method and sources

Counting units

Publications are deduplicated by publication number; applications by application number, so a publication and its grant count once; families by the source family ID. Technology fields are derived automatically from IPC codes using the WIPO IPC–Technology Concordance (March 2026), without manual or AI labeling.

Publication or grant documents do not establish current rights. Check legal status and current owners with the relevant patent office.

Entity scope

These statistics use only the applicant names and publication dates collected for this snapshot. They do not represent the full company or group portfolio.

Search jurisdictions
Worldwide
Applicant-name basis
Dataset-harmonized assignees (not verified current owners)
Applicant names included in these statistics
BEIGENE LTD · BEIGENE SWITZERLAND GMBH · BEONE MEDICINES I GMBH
Reviewed names not covered
BEIGENE, LTD. · BEONE MEDICINES LTD. · 百济神州有限公司
Current entity configuration and review evidence

The reviewed entities and aliases below describe the current company configuration. Only names listed above are covered by this snapshot.

BeOne Medicines I GmbH

Configured aliases: BeiGene Switzerland GmbH · BEIGENE SWITZERLAND GMBH · BEONE MEDICINES I GMBH

Original review note: 2025-05-27 母公司英文名称改为 BeOne Medicines Ltd.;合同明确 BeOne Medicines I GmbH 原名 BeiGene Switzerland GmbH。历史标准名按法人证据归并,不将全部 BeiGene/BeOne 前缀自动纳入。

Review evidence

BeOne Medicines Ltd.

Configured aliases: BeiGene, Ltd. · BEIGENE LTD · 百济神州有限公司

Original review note: 2025-05-27 母公司英文名称改为 BeOne Medicines Ltd.;合同明确 BeOne Medicines I GmbH 原名 BeiGene Switzerland GmbH。历史标准名按法人证据归并,不将全部 BeiGene/BeOne 前缀自动纳入。

Review evidence

Data sources

  • Google Patents · PartialPublished 2025-01-01 to 2025-12-31 · retrieved 2026-11-17 · 385 included · 0 out of scopeSource and terms

Found a wrong attribution or number? Tell us